--- title: "Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy" type: "News" locale: "en" url: "https://longbridge.com/en/news/286419469.md" description: "Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 at the 2026 American Society of Gene and Cell Therapy Annual Meeting. The therapy showed promising results in Type 2 diabetic mouse models, reversing hyperglycemia and improving insulin function. Genprex emphasized the therapy's potential for human application through endoscopic pancreatic delivery, marking a significant advancement towards a treatment that could provide durable glycemic control for Type 2 diabetes patients. The company focuses on gene-based treatments for serious diseases, including diabetes and cancer." datetime: "2026-05-14T12:31:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286419469.md) - [en](https://longbridge.com/en/news/286419469.md) - [zh-HK](https://longbridge.com/zh-HK/news/286419469.md) --- # Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An update from Genprex ( (GNPX) ) is now available. On May 14, 2026, Genprex reported that its research collaborators presented positive preclinical data for its diabetes gene therapy candidate GPX-002 at the 2026 American Society of Gene and Cell Therapy Annual Meeting in Boston, based on experiments conducted on May 13, 2026. In Type 2 diabetic mouse models, pancreatic delivery of the Pdx1/MafA gene therapy reversed hyperglycemia, normalized glucose-stimulated insulin secretion to near healthy levels, and improved insulin granule maturation and beta-cell transcriptomic profiles. The studies showed that both globally targeted and beta-cell–specific delivery approaches significantly enhanced beta-cell function and maturation compared with high-fat-diet controls, suggesting the therapy directly addresses beta-cell dysfunction. Genprex said the procedure is technically translatable to humans via endoscopic pancreatic delivery and described the findings as a pivotal step toward a potentially transformative treatment that could offer more durable glycemic control for Type 2 diabetes patients. **More about Genprex** Genprex, Inc. is a clinical-stage gene therapy company developing novel gene-based treatments for serious diseases, including diabetes and cancer. Its pipeline includes a diabetes gene therapy candidate aimed at restoring pancreatic beta-cell function, targeting large chronic disease markets where current therapies primarily manage symptoms rather than address underlying defects. **Average Trading Volume:** 931,233 **Technical Sentiment Signal:** Sell **Current Market Cap:** $8.65M For an in-depth examination of GNPX stock, go to TipRanks’ Overview page. ### Related Stocks - [GNPX.US](https://longbridge.com/en/quote/GNPX.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [](https://longbridge.com/en/news/286807703.md) - [Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel](https://longbridge.com/en/news/284784032.md) - [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)